Tinengotinib

DB17384InvestigationalSmall molecule

Tinengotinib: Overview.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 2, Macrophage colony-stimulating factor 1 receptor, and Aurora kinase A
Curator reviewed
Formula / weight: C₂₀H₁₉ClN₆O · 394.86 g/mol (avg)
Also known as: 4-(5-(2-Chlorophenyl)-3-Methyl-2,10-Dihydropyrazolo[4,3-B] Pyrido[4,3-E][1,4]Diazepin-8-Yl) Morpholine · 5-(2-chlorophenyl)-3-methyl-8-(morpholin-4-yl)-1,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepine · Pyrazolo(4,3-b)pyrido(4,3-e)(1,4)diazepine, 5-(2-chlorophenyl)-1,2-dihydro-3-methyl-8-(4-morpholinyl)-
Code names: TT-00420

Resolves to

Compound

Structure

InChIKeyDQFCVOOFMXEPOC-UHFFFAOYSA-NSMILESCC1=C2N=C(C3=CC=CC=C3Cl)C3=C(NC2=NN1)C=C(N=C3)N1CCOCC1

Targets

What you can answer from here — as of July 08, 2026

9Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tinengotinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.